Arcutis Biotherapeutics Inc. (ARQT) to Offer $150M in Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Arcutis Biotherapeutics Inc. (ARQT) Prices 5.5M Share Upsized Common Offering at $35/Sh
February 3, 2021 5:41 AM ESTArcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the pricing of its upsized underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $35.00 per share. In addition, Arcutis has granted the... More
